Adverse cardiovascular effects of rofecoxib [1]

New England Journal of Medicine

Volumn 355, Issue 2, 2006, Pages 203-204

  Nissen, Steven E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; ROFECOXIB;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG SAFETY; HEART FAILURE; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; KIDNEY DISEASE; LETTER; POST HOC ANALYSIS; PRIORITY JOURNAL; THROMBOSIS;

CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DATA INTERPRETATION, STATISTICAL; HUMANS; LACTONES; RANDOMIZED CONTROLLED TRIALS; SULFONES;

EID: 33745900534     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc066260     Document Type: Letter

References (3)

1. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106. [Erratum, BMJ 1994;308:1540.]
3. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.